Year in Review: R&D, Regulatory, and Reimbursement

In this ISSUE

Hahn Confirmed as FDA Commissioner

Trade Pact Hits Biopharma Exclusivity

Q&A: Amy Mahery, Global Head of Market Access and Pricing of the healthcare business of Merck KGaA, Darmstadt, Germany

TOP STORY

Year in Review: R&D, Regulatory, and Reimbursement Hurdles

Sponsors developed important new therapies amidst ongoing concerns over drug quality and costs. Jill Wechsler reports
… /Read more/

GLOBAL

The Route to Market Access in Europe

Exploring the roadmap for US-based, R&D-focused biopharma companies seeking to successfully reach patients in Europe
… /Read more/

Text ROI to 55150
Check out this article that reviews some core brand challenges that patient text becomes a natural solution for.
Read the Article

Calendar

/ March 8-11, 2020: Pharma Forum 2020 /

New York City, NY

/ March 18–19, 2020: World Pharma Pricing Market Access & Evidence Congress /

Amsterdam, The Netherlands

/ March 30–31, 2020: 6th Edition Drug Pricing Transparency Congress /

Philadelphia, PA

/ March 31–April 2, 2020: eyeforpharma Barcelona 2020 /

Barcelona, Spain

/ April 20–22, 2020: Digital Health for Pharma /

Philadelphia, PA.

/ April 22–24, 2020: 9th Digital Marketing for Medical Devices West /

Burlingame, CA.

Interview

Taj Bhardwaj, Lundbeck: Market Access and Mental Health

Lundbeck's Taj Bhardwaj talks about leading both local and global-level market access strategies in pharma—and how his current company is committed to the fight to advance new treatments and break down stigmas in mental health
… /Read more/

Evaluating Electronic Benefit Verification Solutions:
What’s available for electronic benefits verification and what to consider as eBV methodologies evolve.

Pricing

International Price Referencing: Stacking the Deck with Lower Income Economies

Ed Schoonveld discusses how cost differences with other countries reflect income differences, how these differences are typical for cost in medical services, and more
… /Read More/

Order-To-Cash Management Fundamentals to Increase Profitability and Reduce Risk
On Demand

AUDIO

The Pharm Exec Podcast: Getting Drug Approval Through FDA LPAD

William Lewis, chairman and CEO of Insmed, talks about the approval of the company’s drug Arikayce through the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs, some ideas that he spoke about on the recent NORD panel about innovative and ethical partnerships, and Insmed’s pipeline and progress
… /Click here to listen/

Industry update

//Kite, a Gilead company, has made two new additions to its leadership team. Charles Calderaro was appointed Global Head of Technical Operations, joining the company from BioMarin. Ken Takeshita was appointed Global Head of Clinical Development. He joins Kit from Sorrento Therapeutics. // Research Partnership’s Philadelphia, PA office has announced a change of leadership from the start of 2020. President Harriet Kozak will be stepping down in order to take retirement at the end of 2019, and will be replaced by Sabera Hyderally, current Director of MedTech, North America, who will take over as the Head of the Philadelphia office January 2, 2020. // InDevR (Boulder, CO) announced that Ms. Terry Salyer joined the company as Chief Commercial Officer.

advertise with us / print subscribe / digital subscribe / visit pharmexec.com